Moxonidine, a mixed alpha(2)-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia.

Article Details

Citation

Copy to clipboard

Stone LS, Fairbanks CA, Wilcox GL

Moxonidine, a mixed alpha(2)-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia.

Ann N Y Acad Sci. 2003 Dec;1009:378-85.

PubMed ID

15028616 [ View in PubMed

]

Abstract

Moxonidine is a mixed alpha(2)-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of alpha(2)-adrenoceptor (alpha(2)AR) agonists, does not require activation of the alpha(2A)AR subtype, which mediates many of the side effects associated with alpha(2)AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Moxonidine	Alpha-2A adrenergic receptor	Protein	Humans	Yes	Agonist	Details